+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Onychomycosis Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4997592
  • Report
  • March 2020
  • Region: Global
  • 115 pages
  • Mordor Intelligence
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Bayer AG
  • Cipla Ltd
  • Galderma S.A.
  • Johnson & Johnson
  • Lumenis Ltd
  • Moberg Pharma AB
  • MORE
The Onychomycosis Treatment Market is expected to register a CAGR of 6.5% during the forecast period. Onychomycosis also known as tinea unguium is a fungal infection of the fingernails or toenails that may involve any component of the nail unit, including the matrix, bed, or plate. This may cause pain, disfigurement, and discomfort and may produce serious issues, and results in reducing quality of life. Onychomycosis is of different types such as superficial onychomycosis, distal and lateral subungual onychomycosis, proximal subungual onychomycosis, endonyx onychomycosis and total dystrophic onychomycosis. Onychomycosis accounts for one third of fungal skin infections because only about one half of nail dystrophies are caused by fungus.

Some of the symptoms of onychomycosis are whitish to yellow-brown discoloration, thickened, distorted in shape, brittle, crumbly or ragged, Smelling slightly foul. Toenail fungal infection can start from foot fungus, and it can spread from one nail to another. Factors that can increase risk of developing nail fungus include diabetes, circulation problems or a weakened immune system, psoriasis, sweating heavily, reduced blood flow and more years of exposure to fungi and slower growing nails.

As per some of the Research studies, estimates up to 10% of adults in Western countries have fungal infection of the nails and this is projected to increase by 20% in adults who are above 60 years of age. In addition, as per study published in PLOS PATHOGENS, prevalence rate of onychomycosis has been reported to be as 23% across Europe, and 20% in East Asia. In North America, the incidence of onychomycosis is up to 14%, with fungal infection responsible for 50% of all nail disease.

Increasing geriatric population, rising prevalence of onychomycosis and diabetic population worldwide and growing awareness about the potential threats of onychomycosis are the key driving factors in onychomycosis treatment market.

Key Market Trends

Drugs Segment is Expected to Hold a Major Market Share in the Onychomycosis Treatment Market
  • Some of the drugs available for the treatment of onychomycosis are terbinafine, ciclopirox, Jublia, fluconazole, Penlac, Ciclodan, ketoconazole, Sporanox, itraconazole, Kerydin, efinaconazole, griseofulvin and so on. For onychomycosis treatment, drugs remain the first line choice of treatment with major market share owing to consistently high success rate.
  • As per Elewski and Charif onychomycosis report, states approximately 40% of elderly population have onychomycosis. Moreover, reduction in nail growth rate ranges from about 40% to 60% in persons more than 65 years of age. Furthermore, onychomycosis affects approximately 2% to 26% of different populations globally. Moreover, less than 30% of infected individuals with onychomycosis seek medical advice or treatment in developed countries.
  • Drugs segment holds a significant market share in the onychomycosis treatment market and is anticipated to show similar trend over the forecast period due to highly effective and easy availability of the products.
  • Rise in geriatric population, increasing availability of treatment options for the condition and growing awareness about early detection of disease are the key driving factors in the drugs segment.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global onychomycosis treatment market due to high drug costs, rising geriatric population, increasing prevalence of onychomycosis and diabetic patient population in this region. As per study published in Journal of Cutaneous Medicine and Surgery, states that prevalence of onychomycosis in the United States is estimated to be at least 12% and rate is high in individuals who are more than 65 years of age.

Competitive Landscape

The onychomycosis treatment market is fragmented competitive and consists of a several major players. Some of the players which are currently dominating the market are Bausch Health Companies Inc (Valeant Pharmaceuticals Inc), Galderma S.A., Novartis AG, Pfizer, Inc, Moberg Pharma AB, Johnson & Johnson, Bayer AG, Dr. Reddy’s Laboratories Ltd, Cipla Ltd, Medimetriks Pharmaceuticals, Inc and Lumenis Ltd.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bayer AG
  • Cipla Ltd
  • Galderma S.A.
  • Johnson & Johnson
  • Lumenis Ltd
  • Moberg Pharma AB
  • MORE
1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Onychomycosis Worldwide
4.2.2 Growing Awareness About the Potential Threats of Onychomycosis
4.3 Market Restraints
4.3.1 Side Effects Associated with Onychomycosis Treatment Drugs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Treatment Type
5.1.1 Drugs
5.1.2 Laser Therapy
5.1.3 Photodynamic Therapy
5.2 By Type
5.2.1 Distal Subungual Onychomycosis
5.2.2 White Superficial Onychomycosis
5.2.3 Proximal Subungual Onychomycosis
5.2.4 Other Types
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bausch Health Companies Inc (Valeant Pharmaceuticals Inc)
6.1.2 Galderma S.A.
6.1.3 Novartis AG
6.1.4 Pfizer, Inc
6.1.5 Moberg Pharma AB
6.1.6 Johnson & Johnson
6.1.7 Bayer AG
6.1.8 Dr. Reddys Laboratories Ltd
6.1.9 Cipla Ltd
6.1.10 Lumenis Ltd
6.1.11 Medimetriks Pharmaceuticals, Inc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Bausch Health Companies Inc (Valeant Pharmaceuticals Inc)
  • Galderma S.A.
  • Novartis AG
  • Pfizer, Inc
  • Moberg Pharma AB
  • Johnson & Johnson
  • Bayer AG
  • Dr. Reddys Laboratories Ltd
  • Cipla Ltd
  • Lumenis Ltd
  • Medimetriks Pharmaceuticals, Inc
Note: Product cover images may vary from those shown
Adroll
adroll